An Observational Study of Herceptin SC Safety in Breast Cancer
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.
Breast Cancer
Safety (composite outcome measure): Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, pregnancies, adverse drug reactions (ADRs); unexpected ADRs; expected ADRs, Up to 6 years
Efficacy: Pathological Complete Response (pCR) in neoadjuvant early breast cancer (EBC), Up to 6 years|Efficacy: Overall response per Response Evaluation Criteria in Solid Tumors (RECIST), Up to 6 years
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.